Behavioural aspects of a modified crosstalk between basal ganglia and limbic system in Parkinson's disease
Dysfunctions in dopaminergic neurotransmission lead to motor symptoms and cognitive impairments associated with behavioural disturbances. Parkinson's disease is a neurodegenerative disorder which is primarily characterized by an abnormal basal ganglia activity. Recently, increased attention has...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
La Découverte Bt.
2016
|
| Sorozat: | Neuropsychopharmacologia Hungarica
18 No. 2 |
| mtmt: | 3092608 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/11337 |
| LEADER | 02084nab a2200229 i 4500 | ||
|---|---|---|---|
| 001 | publ11337 | ||
| 005 | 20191202115610.0 | ||
| 008 | 170516s2016 hu o 0|| zxx d | ||
| 022 | |a 1419-8711 | ||
| 024 | 7 | |a 3092608 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a zxx | ||
| 100 | 1 | |a Györfi Orsolya | |
| 245 | 1 | 0 | |a Behavioural aspects of a modified crosstalk between basal ganglia and limbic system in Parkinson's disease |h [elektronikus dokumentum] / |c Györfi Orsolya |
| 260 | |a La Découverte Bt. |c 2016 | ||
| 300 | |a 87-92 | ||
| 490 | 0 | |a Neuropsychopharmacologia Hungarica |v 18 No. 2 | |
| 520 | 3 | |a Dysfunctions in dopaminergic neurotransmission lead to motor symptoms and cognitive impairments associated with behavioural disturbances. Parkinson's disease is a neurodegenerative disorder which is primarily characterized by an abnormal basal ganglia activity. Recently, increased attention has been directed towards the hippocampus in the development of non-motor symptoms. Given the temporal progression of the disease, dopaminergic depletion firstly affects the dorsal striatum leaving the ventral striatum relatively intact. However, it is possible that the structure and function of the hippocampus shows alterations even in early stages of Parkinson's disease. Subtle cognitive impairments occur in the earliest stages, and therefore Parkinson's disease could provide a unique model to investigate the effect of replacement therapies on a neural network with different baseline dopaminergic levels. Strong evidence suggests that dopaminergic medications improve the motor symptoms, but these medications might have disadvantageous effects on cognitive functions. In this review, we examine the role of dopaminergic changes across several cognitive and behavioural impairments observed in Parkinson's disease, with a special reference to hippocampal dysfunctions. | |
| 700 | 0 | 1 | |a Nagy Helga |e aut |
| 700 | 0 | 1 | |a Bokor Magdolna |e aut |
| 700 | 0 | 1 | |a Kéri Szabolcs |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/11337/1/gyorfi_nph_2016_junius.pdf |z Dokumentum-elérés |